Carl Borrebaeck, professor at the department of Immunotechnology at Lund...
Carl Borrebaeck, professor at the department of Immunotechnology at Lund University.

Source: Apelöga

News • Oncology

Blood test detects early stage pancreatic cancer

Pancreatic cancer is currently very difficult to detect while it is still resectable. A new blood test developed by researchers at Lund University in Sweden, Herlev Hospital, Knight Cancer Center and Immunovia AB, can detect pancreatic cancer in the very earliest stages of the disease.

Due to diffuse symptoms, pancreatic cancer is usually diagnosed very late in the disease progression. Therefore, despite pancreatic cancer representing less than 3% of all cancer cases, more people currently die from it than breast cancer. By 2030, pancreatic cancer is expected to be the second deadliest type of cancer in the world.

"Our test can detect pancreatic cancer with 96% accuracy at stage I and II, while there is still the possibility of successful surgical intervention. There is currently no cure and few treatment options for advanced pancreatic cancer, which is the late stage when pancreatic cancer is usually diagnosed", explains Carl Borrebaeck, professor at the department of Immunotechnology at Lund University.

The study used samples from patients in both Denmark and the US, at different stages of the disease. The blood test is developed on a so-called antibody microarray that consists of hundreds of recombinant antibody fragments. These antibody fragments are specific for a number of immune-regulatory proteins, cancer-associated antigens, and so on.

Since the immune system is the first to respond to threats like complex diseases, such as cancer, autoimmune diseases and infections, the microarray was designed to mirror this early response. This provides information about the development of tumours long before being visible on CT or detected by ctDNA. From those hundreds of markers, 29 markers were selected to detect pancreatic cancer with 96% accuracy at stage I and II.

In the future, the screening method could be used to screen people who are at a higher risk of developing pancreatic cancer, such as those with a hereditary risk, newly onset diabetes patients and patients with chronic inflammation of the pancreas.

The next step has already been initiated, which is a large US prospective study for high risk individuals.

Source: Lund University

20.09.2018

Read all latest stories

Related articles

Photo

News • Liquid biopsy for early detection of brain tumours

Glioblastoma: Mathematical modelling could lead to simple blood test

The development of a simple blood test for glioblastomas could mean earlier diagnosis and more effective and personalised treatment options against the most common type of malignant brain cancer.

Photo

Article • Oncology

Pancreatic cancer - current challenges and future direction

Pancreatic cancer is one of the deadliest cancers in the world, and one of the most difficult to treat. In 2020, an estimated 495,000 individuals worldwide were diagnosed with pancreatic cancer and…

Photo

News • Oncology early detection tool

Blood test for 50+ types of cancer promising for screening

Final results from a study of a blood test that can detect more than 50 types of cancer have shown that it is accurate enough to be rolled out as a multi-cancer screening test among people at higher…

Related products

Nova Biomedical – StatStrip Glucose/Ketone*

Blood Glucose

Nova Biomedical – StatStrip Glucose/Ketone*

Nova Biomedical Corporation
Sarstedt – Tempus600 Vita

Sample Logistics

Sarstedt – Tempus600 Vita

SARSTEDT AG & CO. KG
Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Clinical Chemistry

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Beckman Coulter – Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter Diagnostics
Beckman Coulter – Early Sepsis Indicator

Blood Cell Counter

Beckman Coulter – Early Sepsis Indicator

Beckman Coulter Diagnostics
Subscribe to Newsletter